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ABSTRACT. Early placental development can be determined by measuring placental growth factor or Placental 
growth factor (PlGF) through the mother's blood since the first trimester of pregnancy. The purpose of this study 
was to determine the effect of supplementation on the development didrogesteron placenta in pregnancy by 
measuring the levels of PlGF. This study is a randomized double-blind clinical trial (Randomized Controlled 
Clinical Trial) held at the Antenatal Clinic (ANC) at the General Hospital dr. Zainoel Abidin (RSUZA), Banda Aceh 
to women of reproductive age in the first trimester in RSUZA ANC checkup. Nonprobability sampling sampling 
with consecutive sampling. In this study there were two groups of women of reproductive age who are not in 
pairs is given didrogesteron group A while group B received placebo. Measurement of PlGF levels in both groups 
performed before and after treatment. PlGF levels prior to treatment in Group A 25.95 pg/ml while Group B 
40.80 pg/ml. PlGF levels after the measurement results given didrogesteron in Group A for 4 weeks gained 
increasing levels of PlGF is 212.15 pg/ml, whereas in group B were given a placebo for 4 weeks was 89.60 
pg/ml. Data analysis was performed using bivariate analysis between supplementation didrogesteron and PlGF 
levels using SPSS 17. Analysis of data for comparative analytical numerical information unpaired two groups: 
Group A: the results of a PlGF levels in pregnant subjects were given didrogesteron and Group B: the results of 
a PlGF levels in pregnant patients given placebo. Unpaired t-test results of the two groups showed that the 
group receiving didrogesteron have elevated levels of PlGF were significantly (p = 0.000 or p < 0.05) compared 
with the placebo group were only given alone. From these results it can be concluded that the administration 
can trigger didrogesteron PlGF levels in women of reproductive age.  
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Introduction 
Currently, there are more than 80% incidence of spontaneous miscarriages occurs at less 
than 12 weeks gestation. Previous studies also shows that the incidence of spontaneous 
miscarriages occurs in approximately 15% of all couples who is trying to conceive. It means 
that at least 1 of 6 couples who has successfully conceive is going to have a miscarriage. 
However 40-50% incidence of miscarriage causes are not yet known. Lately, there is a 
popular suggestion concerning a possible link between the incidence of miscarriage with 
maternal immune response to fetal antigen. Maternal immune system response against fetal 
antigens can occur because fetus and placenta consist of paternal antigens. Progesterone 
can induce tolerance of maternal immune system to the fetal paternal antigen. Progestin 
use during first trimester of pregnancy has been widely used either by physicians or 
midwives. However, routine progestin use in normal pregnant women has never been 
investigated before. Placental Growth Factor (PlGF) is a homodimer glycoprotein that is 
homologous to Vascular Endothelial Growth Factor (VEGF) produced by trophoblastic cells. 
Therefore, currently PlGF commonly used as an indicator on placental development and can 
also being used as predictor on obstetric complications related to placental disorders such 
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as pre-eclampsia and intra-uterine growth retardation (IUGR). This study is trying to 
observe the effect of progestin treatment during first trimester to normal pregnant women 
on placental development that will be measured by the level of PlGF. 
Materials and Methods 
A randomized controlled clinical trial was done to women who were having routine antenatal 
care at 6-8 weeks of gestation, at RSU Zainoel Abidin (RSUZA), Banda Aceh, from April to 
November 2012. Study participants have been divided randomly into group A 
(Dydrogesterone 2x10 mg and Folic acid 1x5 mg for 4 weeks), and group B (Folic acid 1x5 
mg for 4 weeks). Blood specimen was taken before drug administration and at 18th weeks of 
gestation for PlGF measurement. 
Result and Discussion 
40 pregnant women were recruited for this study. The mean age between group A and B is 
28.60 vs. 27.85, which is not statistically significant (p > 0.05). The mean number of 
pregnancy between group A and B is 2.35 vs. 2.15, which is not statistically significant (p > 
0.05). The mean number of parity between group A and B is 1.35 vs. 1.15, which is not 
statistically significant (p > 0.05). The mean of gestational age between group A and B is 
6.85 vs. 7.25 weeks, which is not statistically significant (p > 0.05). The mean body weight 
between group A and B is 58.95 56.85 kilogram, which is not statistically significant (p > 
0.05). 
Table 1. Data on research population based-group. 
Indicator Group A Group B P value 
Age (years) 28.60 (20-40) 27.85 (20-37) 0,659 (p>0.05) 
Gravida (no. Of pregnancy) 2.35 (1-5) 2.15 (1-5) 0.649 (p>0.05) 
Parity (no. Of live child) 1.35 (0-4) 1.15 (0-4) 0.649 (p>0.05) 
Gestational Age (weeks) 6.85 (6-8)  7.25 (6-8) 0.202(p>0.05) 
Weight (Kg) 58.95 (38-80) 56.85 (40-72) 0.468 (p>0.05) 
 
The mean levels of PlGF between each groups before medication shows no significant 
difference 25.95 vs. 40.80 pg/mL (p = 0091 or p> 0.05). The mean levels of PlGF in group 
A after receiving medication is 212.15 pg/mL, which shows an elevation of 186.20 pg / mL. 
The results of a paired t test for PlGF levels in group A before and after treatment shows 
significant difference (p = 0.000 or p <0.05). The mean levels of PlGF in group B after 
receiving medication is 89.60 pg/mL, which shows an elevation of 48.8 pg/mL. The results 
of a paired t test for PlGF levels in group B before and after treatment shows significant 
difference (p = 0.000 or p <0.05). Group A shows higher increase on PlGF level increase 
compared to group B after medication (186.20 vs. 48.80 pg/mL), and the difference on PlGF 
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level after being treated between each group shows significant difference (p = 0.000 or p 
<0.05). 
 
  Table 2. Data on PlGF level between each group before and after treatment 
 Pre Post P value 
Group A 25.95 212.15 0.000 (p < 0.05) 
Group B 40.80 89.60 0.000 (p <0.05) 
 
 Table 3. Data on PlGF level increase after treatment 
 Group A Group B P value 
The level of increase 
on PlGF level 
186.20 48.80 0.000 (p<0.05) 
 
 
Figure 1. Individual changes on PlGF level between each group before and after treatment  
Conclusion 
This study demonstrated that the administration of Dydrogesterone during first trimester of 
pregnancy in normal pregnant women can induce higher PlGF level in 18th weeks of 
gestation. 
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